Migraine Prophylaxis Guideline
Recommended Medications
- The 2023 VA/DoD Clinical Practice Guideline for the Management of Headache recommends candesartan or telmisartan as first-line options for migraine prophylaxis, with a strong recommendation 1
- The American College of Cardiology is not mentioned, however the 2023 VA/DoD guideline strongly recommends CGRP monoclonal antibodies, such as erenumab, fremanezumab, or galcanezumab, for migraine prophylaxis 1
- The 2023 VA/DoD Clinical Practice Guideline for the Management of Headache recommends topiramate, valproate, propranolol, lisinopril, oral magnesium, memantine, atogepant, and onabotulinumtoxinA (for chronic migraine only) as alternative options for migraine prophylaxis, with a weak recommendation 1
Non-Recommended Medications
- The 2023 VA/DoD Clinical Practice Guideline for the Management of Headache does not recommend lamotrigine for migraine prophylaxis due to lack of efficacy for reducing migraine frequency in clinical trials 1
- The guideline specifically recommends against gabapentin for migraine prophylaxis, suggesting insufficient evidence to warrant inclusion, and by extension, implies that lamotrigine should not be used as a general migraine prophylactic agent due to similar concerns 1
Medication Considerations
- Clinicians should select medications with established efficacy for migraine prophylaxis as outlined in current guidelines, such as those recommended by the 2023 VA/DoD Clinical Practice Guideline for the Management of Headache 1